Netherlands · Delayed Price · Currency is EUR Pharming Group Statistics
Total Valuation
Pharming Group has a market cap or net worth of EUR 784.58 million. The enterprise value is 718.49 million.
| Market Cap | 784.58M |
| Enterprise Value | 718.49M |
Important Dates
The last earnings date was Tuesday, October 27, 2026.
| Earnings Date | Oct 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Pharming Group has 707.78 million shares outstanding. The number of shares has increased by 33.62% in one year.
| Current Share Class | 707.78M |
| Shares Outstanding | 707.78M |
| Shares Change (YoY) | +33.62% |
| Shares Change (QoQ) | +27.86% |
| Owned by Insiders (%) | 1.58% |
| Owned by Institutions (%) | 20.59% |
| Float | 696.57M |
Valuation Ratios
The trailing PE ratio is 43.90 and the forward PE ratio is 33.65.
| PE Ratio | 43.90 |
| Forward PE | 33.65 |
| PS Ratio | 2.37 |
| PB Ratio | 3.15 |
| P/TBV Ratio | 5.54 |
| P/FCF Ratio | 26.58 |
| P/OCF Ratio | 25.93 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.67, with an EV/FCF ratio of 24.41.
| EV / Earnings | 34.82 |
| EV / Sales | 2.18 |
| EV / EBITDA | 13.67 |
| EV / EBIT | 16.66 |
| EV / FCF | 24.41 |
Financial Position
The company has a current ratio of 3.23, with a Debt / Equity ratio of 0.39.
| Current Ratio | 3.23 |
| Quick Ratio | 2.65 |
| Debt / Equity | 0.39 |
| Debt / EBITDA | 1.89 |
| Debt / FCF | 3.32 |
| Interest Coverage | 8.50 |
Financial Efficiency
Return on equity (ROE) is 8.70% and return on invested capital (ROIC) is 15.76%.
| Return on Equity (ROE) | 8.70% |
| Return on Assets (ROA) | 6.37% |
| Return on Invested Capital (ROIC) | 15.76% |
| Return on Capital Employed (ROCE) | 12.46% |
| Weighted Average Cost of Capital (WACC) | 4.45% |
| Revenue Per Employee | 836,784 |
| Profits Per Employee | 52,319 |
| Employee Count | 407 |
| Asset Turnover | 0.80 |
| Inventory Turnover | 0.76 |
Taxes
In the past 12 months, Pharming Group has paid 8.94 million in taxes.
| Income Tax | 8.94M |
| Effective Tax Rate | 29.56% |
Stock Price Statistics
The stock price has decreased by -1.90% in the last 52 weeks. The beta is 0.06, so Pharming Group's price volatility has been lower than the market average.
| Beta (5Y) | 0.06 |
| 52-Week Price Change | -1.90% |
| 50-Day Moving Average | 0.94 |
| 200-Day Moving Average | 1.18 |
| Relative Strength Index (RSI) | 71.13 |
| Average Volume (20 Days) | 10,596,219 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Pharming Group had revenue of EUR 340.57 million and earned 21.29 million in profits. Earnings per share was 0.03.
| Revenue | 340.57M |
| Gross Profit | 298.58M |
| Operating Income | 43.52M |
| Pretax Income | 30.23M |
| Net Income | 21.29M |
| EBITDA | 50.20M |
| EBIT | 43.52M |
| Earnings Per Share (EPS) | 0.03 |
Balance Sheet
The company has 166.93 million in cash and 100.84 million in debt, with a net cash position of 66.09 million or 0.09 per share.
| Cash & Cash Equivalents | 166.93M |
| Total Debt | 100.84M |
| Net Cash | 66.09M |
| Net Cash Per Share | 0.09 |
| Equity (Book Value) | 256.47M |
| Book Value Per Share | 0.37 |
| Working Capital | 195.87M |
Cash Flow
In the last 12 months, operating cash flow was 31.15 million and capital expenditures -766,122, giving a free cash flow of 30.38 million.
| Operating Cash Flow | 31.15M |
| Capital Expenditures | -766,122 |
| Depreciation & Amortization | 6.76M |
| Net Borrowing | -14.39M |
| Free Cash Flow | 30.38M |
| FCF Per Share | 0.04 |
Margins
Gross margin is 87.67%, with operating and profit margins of 12.78% and 6.25%.
| Gross Margin | 87.67% |
| Operating Margin | 12.78% |
| Pretax Margin | 8.88% |
| Profit Margin | 6.25% |
| EBITDA Margin | 14.74% |
| EBIT Margin | 12.78% |
| FCF Margin | 8.83% |
Dividends & Yields
Pharming Group does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -33.62% |
| Shareholder Yield | -33.62% |
| Earnings Yield | 2.28% |
| FCF Yield | 3.76% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Pharming Group is 2.21, which is 99.55% higher than the current price. The consensus rating is "Buy".
| Price Target | 2.21 |
| Price Target Difference | 99.55% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | 5.36% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
The last stock split was on March 5, 2013. It was a reverse split with a ratio of 0.1.
| Last Split Date | Mar 5, 2013 |
| Split Type | Reverse |
| Split Ratio | 0.1 |
Scores
Pharming Group has an Altman Z-Score of 3.9 and a Piotroski F-Score of 5.
| Altman Z-Score | 3.9 |
| Piotroski F-Score | 5 |